You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
The Medtronic HVAD™ System is a full-support, durable left ventricular assist device (VAD) that received the CE mark for a less-invasive thoracotomy approach, destination therapy, and bridge to transplant.ABOUT HVAD THERAPY
The HVAD Pump is engineered for reliability and durability.
The pump's passive maglev with hydrodynamic bearings means there's no need for electronic sensors or mechanical bearings. This results in a less complex system that eliminates friction, heat, and component wear.2
Dual motor stators enhance efficiency and provide redundancy to rotate the impeller.2
A patented, wide-blade impeller features three blood flow paths. These are designed to enhance blood flow and reduce blood trauma while reducing the time blood travels through the device.2
The unique, integrated inflow cannula design offers the flexibility to fit into smaller-framed patients and treat more complex patients.3-8 It also allows for stable inflow position, even with body habitus changes.9
30% smaller than other devices11
20% lighter than other devices11
38% less displaced volume11
Living with the
Unique to the HVAD System is smart technology that enables clinicians to access and download data to gain insights into the pump’s performance. Autologs™ 1.3, the latest update to our advanced device management service, provides clinicians with faster access to important pump data, and deeper insights into the chronology of events.
The HVAD™ System was the first LVAD approved for the less-invasive thoracotomy approach12 and it is also the only full-support, durable VAD with clinical evidence to prove its safety and effectiveness when used in a thoracotomy approach. HVAD implantation via the less-invasive thoracotomy approach has resulted in improved quality of life, reduced adverse events, and an unprecedented survival rate.13, 14LEARN MORE
The Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) was a multicenter registry that collected post-CE-mark clinical data on patients implanted with the HVAD System as a bridge to transplant (BTT). It demonstrated extended survival on the HVAD System:
A recent analysis found that HVAD implantation via the less-invasive thoracotomy approach resulted in:
The latest clinical evidence from the HVAD LATERAL Trial demonstrated a significant improvement in quality of life:
Interested in learning more about the HVAD System and the less-invasive thoracotomy approach? Medtronic offers educational programs designed for clinicians interested in expanding their knowledge of VAD therapy and the HVAD System. To learn more about these educational opportunities, please speak with your Medtronic sales representative or register to access Medtronic Academy. Once you are registered, login and search for MCS.SEE EDUCATION OFFERINGS
HVAD System Instructions for Use. HeartWare Inc. Framingham, MA USA 07/18. HeartMate 3 Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA (02/17).
Larose JA, Tamez D, Ashenuga M, Reyes C. Design concepts and principle of operation of the HeartWare ventricular assist system. ASAIO J. July-August 2010;56(4):285-289.
Abicht T, Gordon R, Meehan K, Stosor V, McCarthy P, McGee E Jr. Complex HeartMate II infection treated with pump exchange to HeartWare HVAD. ASAIO J. March-April 2013;59(2):188-192.
Gregoric ID, Cohn WE, Frazier OH. Diaphragmatic Implantation of the HeartWare Ventricular Assist Device. J Heart Lung Transplant. April 2011;30(4):467-470.
Takeda K, Ahmad U, Malaisrie SC, Lee R, McCarthy PM, McGee EC Jr. Successful implantation of HeartWare HVAD left ventricular assist device with concomitant ascending and sinus of valsalva aneurysms repair. J Artif Organs. June 2012;15(2):204-206.
Morshuis M, Boergermann J, Gummert J, Koster A. A modified technique for implantation of the HeartWare™ left ventricular assist device when using bivalirudin anticoagulation in patients with acute heparin-induced thrombocytopenia. Interact Cardiovasc Thorac Surg. August 2013;17(2):225-226.
Palmen M, Verwey HF, Haeck ML, Holman ER, Schalij MJ, Klautz RJ. Implantation of a left ventricular assist device in patients with a complex apical anatomy. Ann Thorac Surg. December 2012;94(6):2122-2125.
Sorensen EN, Hiivala NJ, Jeudy J, Rajagopal K, Griffith BP. Computed tomography correlates of inflow cannula malposition in a continuous-flow ventricular-assist-device. J Heart Lung Transplant. June 2013;32(6):654-657.
Huang J, Slaughter MS. HeartWare ventricular assist device placement with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg. February 2013;145(2):e23-25.
Sabashnikov A, Mohite PN, Zych B, et al. Outcomes in patients receiving Heartmate II versus HVAD left ventricular device as a bridge to transplantation. Transplant Proc. June 2014;46(5):1469-1475.
Data extrapolated based on source data from: HVAD System Instructions for Use. HeartWare Inc., Miami Lakes, MA, USA. July 2018. Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA. October 2017.
HVAD thoracotomy approval comparison with competitor. October 2020. Medtronic data on file.
McGee E Jr, Danter M, Strueber M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. J Heart Lung Transplant. April 2019;38(4):344-351.
Wieselthaler G, et al. Temporal Adverse Event Profile following LVAD Implantation via a Thoracotomy Approach: 2 Year Follow-up of the LATERAL Trial. Presented at ASAIO 2019; San Francisco, CA.
Zimpfer D, Fiane AE, Larbalestier R, et al. Long-Term Survival of Patients With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended as a Bridge to Transplantation: The Registry to Evaluate the HeartWare Left Ventricular Assist System. Circ Heart Fail. March 2020;13(3):e006252.
Mokadam NA, McGee E, Wieselthaler G, et al. Cost of Thoracotomy Approach: An Analysis of the LATERAL Trial. Ann Thorac Surg. November 2020;110(5):1512-1519.